A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKERADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITHLENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORYFOLLICULAR LYMPHOMA
Contact:
NCT Number:
Protocol:
AAAT0518
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/III
The purpose of the study is to evaluate the safety and tolerability of tazemetostat in combination with lenalidomide + rituximab in patients with follicular lymphoma that has returned or has not responded to treatment (relapsed/refractory). The study will also try to select a recommended phase 3 dose of tazemetostat for further evaluation.
Are you Eligible? (Inclusion Criteria)
- Are you 18 years of age or older?
- Do you have follicular lymphoma?
- Has your disease relapsed or progressed during/after treatment?
- Are you able to take oral medication?
Specialty Area(s)
Lymphoma, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
